← Oncology Approval Tracker

FDA DECISION ·

Oxderys

doxorubicin hydrochloride injection · AVYXA Holdings

FDA approvalNew product approvalMultiple solid tumors and hematologic malignancies
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Doxorubicin injection for multi-agent adjuvant treatment of node-positive breast cancer after resection, and the leukemias, lymphomas and metastatic solid tumors specified in its FDA labeling. The full label defines each authorized use.

SUPPORTING DATA

Evidence behind the decision

Study
NDA 221093: original product approval under section 505(b)(2).
Key result
FDA authorized the product for the uses in its agreed labeling; no comparative superiority is established by the approval letter.
Safety to report
Boxed warnings cover cardiomyopathy, secondary malignancies, extravasation/tissue necrosis and severe myelosuppression.
Evidence limits
Approval does not establish commercial availability, a new mechanism or an efficacy advantage over other doxorubicin products.

LAMPGEN ANALYSIS

Why it matters

An original 505(b)(2) product NDA for an established active ingredient. This action is neither a new molecular entity nor a first-generic approval.

What research teams should watch

Check the exact vial presentation, pharmacy preparation, cumulative anthracycline exposure and extravasation procedures against the study protocol and approved label.

PRIMARY RECORDS

Sources